Patient baseline characteristics
| . | Total . | Imatinib-resistant . | Imatinib-intolerant . |
|---|---|---|---|
| No. patients | 107 | 99 | 8 |
| Median age, y (range) | 57 (23-86) | 57 (23-86) | 67 (54-74) |
| Male sex, % | 51 | 54 | 25 |
| Median duration of CML, mo | 90.9 | 91.2 | 68.7 |
| Extramedullary involvement, no. (%) | |||
| Spleen | 18 (17) | 16 (16) | 2 (25) |
| Outside spleen | 5 (5) | 5 (5) | 0 (0) |
| Median WBC count, mm3 (range) | 16.8 (1.0-243.4) | 17.5 (1.0-243.4) | 5.6 (3.2-68.4) |
| WBC count of at least 20 000/mm3, % | 42 | 42 | 38 |
| Median marrow blasts | 9.0 | 8.9 | 15.0 |
| Marrow blasts at least 15%, % | 33 | 31 | 50 |
| Median peripheral blasts | 2.5 | 2.0 | 7.0 |
| Peripheral blasts at least 15%, % | 13 | 13 | 13 |
| Median platelet count, no. (range) | 165 (8-3580) | 165 (8-3580) | 166 (54-1463) |
| Platelet count below 100 000/mm3, no. (%) | 44 (41) | 40 (40) | 4 (50) |
| Basophils at least 20%, no. (%) | 20 (19) | 20 (20) | 0 (0) |
| BCR-ABL mutation, no. (%)* | 56/98 (57) | 55/90 (61) | 1/8 (13) |
| Imatinib therapy duration, % | |||
| Less than 1 y | 8 | 4 | 50 |
| 1-3 y | 24 | 24 | 25 |
| Longer than 3 y | 68 | 72 | 25 |
| Highest imatinib dose, % | |||
| 400-600 mg | 41 | 39 | 63 |
| More than 600 mg | 59 | 61 | 38 |
| Prior chemotherapy, % | 67 | 69 | 50 |
| Prior interferon-α, % | 75 | 77 | 50 |
| Prior SCT, % | 18 | 17 | 25 |
| Baseline grade 3-4 hematologic toxicity, % | |||
| Leukopenia | 5 | 5 | 0 |
| Thrombocytopenia | 25 | 25 | 0 |
| Neutropenia | 7 | 7 | 0 |
| Anemia | 5 | 5 | 0 |
| . | Total . | Imatinib-resistant . | Imatinib-intolerant . |
|---|---|---|---|
| No. patients | 107 | 99 | 8 |
| Median age, y (range) | 57 (23-86) | 57 (23-86) | 67 (54-74) |
| Male sex, % | 51 | 54 | 25 |
| Median duration of CML, mo | 90.9 | 91.2 | 68.7 |
| Extramedullary involvement, no. (%) | |||
| Spleen | 18 (17) | 16 (16) | 2 (25) |
| Outside spleen | 5 (5) | 5 (5) | 0 (0) |
| Median WBC count, mm3 (range) | 16.8 (1.0-243.4) | 17.5 (1.0-243.4) | 5.6 (3.2-68.4) |
| WBC count of at least 20 000/mm3, % | 42 | 42 | 38 |
| Median marrow blasts | 9.0 | 8.9 | 15.0 |
| Marrow blasts at least 15%, % | 33 | 31 | 50 |
| Median peripheral blasts | 2.5 | 2.0 | 7.0 |
| Peripheral blasts at least 15%, % | 13 | 13 | 13 |
| Median platelet count, no. (range) | 165 (8-3580) | 165 (8-3580) | 166 (54-1463) |
| Platelet count below 100 000/mm3, no. (%) | 44 (41) | 40 (40) | 4 (50) |
| Basophils at least 20%, no. (%) | 20 (19) | 20 (20) | 0 (0) |
| BCR-ABL mutation, no. (%)* | 56/98 (57) | 55/90 (61) | 1/8 (13) |
| Imatinib therapy duration, % | |||
| Less than 1 y | 8 | 4 | 50 |
| 1-3 y | 24 | 24 | 25 |
| Longer than 3 y | 68 | 72 | 25 |
| Highest imatinib dose, % | |||
| 400-600 mg | 41 | 39 | 63 |
| More than 600 mg | 59 | 61 | 38 |
| Prior chemotherapy, % | 67 | 69 | 50 |
| Prior interferon-α, % | 75 | 77 | 50 |
| Prior SCT, % | 18 | 17 | 25 |
| Baseline grade 3-4 hematologic toxicity, % | |||
| Leukopenia | 5 | 5 | 0 |
| Thrombocytopenia | 25 | 25 | 0 |
| Neutropenia | 7 | 7 | 0 |
| Anemia | 5 | 5 | 0 |
WBC indicates white blood cell; SCT, stem cell transplantation.
Percentage is based on number of patients with baseline mutation analysis available.